Is PT-141 the same as Vyleesi?
Yes, as a name. Vyleesi is the FDA approved brand for bremelanotide, which this site's PT-141 profile lists as another name, along with Vyleesi. Its June 2019 approval covers low sexual desire that causes distress in women who have not reached menopause, based on RECONNECT, in 1,267 women over 24 weeks. A research-chemical vial labeled PT-141 is not that labeled pen. The molecule name can match. The finished drug and the unlabeled vial are not the same product. This site does not rank brands.
Studies in people from the compound pages this answer belongs to
- PT-141
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT) 2019 PMID 31599840
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder 2019 PMID 31599847
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide 2017 PMID 27977473
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of further names and published absences. Leftover harvested questions after the first two absence sets: more brand versus molecule names, side effects the citations did not count, compounding formulas this catalogue does not hold, national FDA and Australia fields, trial windows rather than an onset clock, named combinations with no interaction table, and oral routes that have not been studied.